吉非替尼联合脑室腹腔分流治疗以恶性颅内高压为初发症状的肺腺癌脑膜转移患者的疗效
发布时间：2018-11-09 15:52
【摘要】：目的 :探讨脑室腹腔分流手术治疗恶性颅内高压为初发症状的肺腺癌脑膜转移的临床效果。方法 :回顾性分析本院收治的21例表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变的肺腺癌脑膜转移患者的临床资料,根据治疗方案将患者分为观察组(吉非替尼联合脑室腹腔分流组11例)和对照组(吉非替尼组10例),对2组的治疗效果进行比较。结果 :观察组的脑脊液癌细胞转阴率为63.6%,对照组的脑脊液癌细胞转阴率为40.0%,两组比较差异无统计学意义(P0.05);观察组症状缓解率为90.9%,对照组症状缓解率为40.0%,两组比较差异有统计学意义(P0.05);观察组的中位无进展生存期为7.8个月,对照组中位无进展生存期为5.3个月,两组比较差异有统计学意义(P=0.014)。结论 :以恶性颅内高压为初发症状的EGFR基因突变的肺腺癌脑膜转移患者接受吉非替尼联合脑室腹腔分流取得了较好的治疗效果,有望成为EGFR基因突变的肺腺癌脑膜转移患者的治疗方案。
[Abstract]:Objective: to investigate the clinical effect of intraventricular and peritoneal shunt in the treatment of meningeal metastasis of lung adenocarcinoma with malignant intracranial hypertension. Methods: the clinical data of 21 patients with meningeal metastasis with epidermal growth factor receptor (epidermal growth factor receptor,EGFR) gene mutation were retrospectively analyzed. Patients were divided into observation group (11 cases) and control group (10 cases) according to the treatment plan. The therapeutic effects of the two groups were compared. Results: the negative rate of CSF cancer cells in the observation group was 63.6 and that in the control group was 40.0.The difference between the two groups was not statistically significant (P0.05). The remission rate of symptoms was 90.9 in the observation group and 40.0 in the control group. The difference between the two groups was statistically significant (P0.05). The median progression-free survival time was 7.8 months in the observation group and 5.3 months in the control group. The difference between the two groups was statistically significant (P0. 014). Conclusion: the patients with meningeal metastasis of lung adenocarcinoma with EGFR gene mutation taking malignant intracranial hypertension as the initial symptom were treated with gifitinib combined with ventriculoperitoneal shunt. It is expected to be a therapeutic regimen for patients with meningeal metastasis of lung adenocarcinoma with EGFR gene mutation.
【作者单位】： 郑州大学人民医院肿瘤内科;郑州大学人民医院神经外科;郑州大学人民医院放射科;郑州大学人民医院放疗科;郑州大学人民医院胸外科;
【分类号】：R734.2
本文编号：2320861
[Abstract]:Objective: to investigate the clinical effect of intraventricular and peritoneal shunt in the treatment of meningeal metastasis of lung adenocarcinoma with malignant intracranial hypertension. Methods: the clinical data of 21 patients with meningeal metastasis with epidermal growth factor receptor (epidermal growth factor receptor,EGFR) gene mutation were retrospectively analyzed. Patients were divided into observation group (11 cases) and control group (10 cases) according to the treatment plan. The therapeutic effects of the two groups were compared. Results: the negative rate of CSF cancer cells in the observation group was 63.6 and that in the control group was 40.0.The difference between the two groups was not statistically significant (P0.05). The remission rate of symptoms was 90.9 in the observation group and 40.0 in the control group. The difference between the two groups was statistically significant (P0.05). The median progression-free survival time was 7.8 months in the observation group and 5.3 months in the control group. The difference between the two groups was statistically significant (P0. 014). Conclusion: the patients with meningeal metastasis of lung adenocarcinoma with EGFR gene mutation taking malignant intracranial hypertension as the initial symptom were treated with gifitinib combined with ventriculoperitoneal shunt. It is expected to be a therapeutic regimen for patients with meningeal metastasis of lung adenocarcinoma with EGFR gene mutation.
【作者单位】： 郑州大学人民医院肿瘤内科;郑州大学人民医院神经外科;郑州大学人民医院放射科;郑州大学人民医院放疗科;郑州大学人民医院胸外科;
【分类号】：R734.2
【相似文献】
相关期刊论文 前4条
1 邵志坚,何泽明,金小民,杨春盛;肺腺癌脑膜转移2例[J];临床肿瘤学杂志;1999年02期
2 王勇;高烨;许德志;朱玉方;徐军;王秀华;陶荣杰;;经Ommaya囊脑室内化学治疗肺腺癌脑膜转移[J];中国临床神经外科杂志;2013年04期
3 赵海涛;王勇;许德志;朱玉方;徐军;陶荣杰;;脑室腹腔分流加Ommaya囊置入配合放化疗治疗肺腺癌脑膜转移的临床观察[J];肿瘤防治研究;2013年10期
4 ;[J];;年期
，本文编号：2320861
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2320861.html
